Pulmonx Corp
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company focused on minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its principal product is the Zephyr Endobronchial Valve, implanted through a bronchoscope to reduce lung… From the company’s description.
Over the twelve months to Sep 30, 2026, Pulmonx Corp reported revenue of $88.78M, down 3.2% from a year earlier, and a net loss of $42.55M. Its operating margin was −44.4%, and operations used $25.58M in cash. In fiscal 2025, it reported revenue of $90.50M, up 8.0% from fiscal 2024, and a net loss of $54.00M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pulmonx Corp does
In the company’s own words
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company focused on minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its principal product is the Zephyr Endobronchial Valve, implanted through a bronchoscope to reduce lung hyperinflation in selected patients. The treatment process uses the Chartis Pulmonary Assessment System to assess collateral ventilation and the cloud-based LungTraX Platform to analyze lung CT scans and help physicians identify and plan treatment for candidates. Pulmonx sells primarily to hospitals, where interventional pulmonologists perform the procedures, using a direct sales organization in the United States and a mix of direct sales and distributors internationally. It also manufactures the AeriSeal System, a foam designed to close collateral air channels that is undergoing clinical development for the U.S. market. Pulmonx generated $90.5 million in revenue for fiscal 2025, primarily from Zephyr Valves and delivery catheters, with smaller contributions from Chartis and LungTraX.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- REDWOOD CITY, CA
- Fiscal year end
- December
- CIK
- 1127537
- SIC
- 3841
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pulmonx Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Pulmonx Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pulmonx Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pulmonx Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pulmonx Corp's last four quarterly filings that the numbers alone won't show?”